{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T15:52:05Z","timestamp":1782489125778,"version":"3.54.5"},"reference-count":38,"publisher":"MDPI AG","issue":"21","license":[{"start":{"date-parts":[[2020,10,23]],"date-time":"2020-10-23T00:00:00Z","timestamp":1603411200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>Vascular endothelial growth factor (VEGF) expression increased significantly in the pathogenesis of age-related macular degeneration, which induced the formation of pathological blood vessels. Dexamethasone is an exogenous anti-angiogenic drug while bevacizumab is an endogenous anti-angiogenic drug. They both have been widely used in ophthalmology. However, independent administration is not enough to completely block the development of choroidal neovascularization (CNV), and the number of eyes vitreous injections is limited. Reasonable combination of drugs may produce significantly better therapeutic effect than single drug treatment. The cyclic RGD (cRGD) peptide has a particularly high affinity with retinal pigment epithelial cells, where VEGF secretes from. In this study, we prepared nanoparticles of bevacizumab and dexamethasone with cRGD peptide as the target (aBev\/cRGD-DPPNs). The particle size of the aBev\/cRGD-DPPNs was 213.8 \u00b1 1.5 nm, SEM results showed that the nano-carriers were well dispersed and spherical. The cell uptake study demonstrated the selectivity of the aBev\/cRGD-DPPN to ARPE-19 with \u03b1V\u03b23 over expressed. The aBev\/cRGD-DPPNs had a better apoptosis induction effect and an obvious inhibitory effect on migration, invasion, and capillary-like structures formation of human umbilical vein epithelial cells. The fluorescein fundus angiography study, immunohistochemistry and histopathological evaluation showed the aBev\/cRGD-DPPNs greatly reduced the development of CNV on a rabbit model.<\/jats:p>","DOI":"10.3390\/molecules25214897","type":"journal-article","created":{"date-parts":[[2020,10,23]],"date-time":"2020-10-23T02:44:12Z","timestamp":1603421052000},"page":"4897","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Cyclic RGD Peptide Targeting Coated Nano Drug Co-Delivery System for Therapeutic Use in Age-Related Macular Degeneration Disease"],"prefix":"10.3390","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8770-2093","authenticated-orcid":false,"given":"Jiaxin","family":"Liu","sequence":"first","affiliation":[{"name":"School of Life Sciences, Jilin University, Changchun 130012, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lifu","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Second Clinical College of Norman Bethune Medical Division, Jilin University, Changchun 130041, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Xu","sequence":"additional","affiliation":[{"name":"School of Life Sciences, Jilin University, Changchun 130012, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ge","family":"Li","sequence":"additional","affiliation":[{"name":"School of Life Sciences, Jilin University, Changchun 130012, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jicong","family":"Chen","sequence":"additional","affiliation":[{"name":"School of Life Sciences, Jilin University, Changchun 130012, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1623-5384","authenticated-orcid":false,"given":"Lesheng","family":"Teng","sequence":"additional","affiliation":[{"name":"School of Life Sciences, Jilin University, Changchun 130012, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0812-744X","authenticated-orcid":false,"given":"Youxin","family":"Li","sequence":"additional","affiliation":[{"name":"School of Life Sciences, Jilin University, Changchun 130012, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6199-9311","authenticated-orcid":false,"given":"Fengying","family":"Sun","sequence":"additional","affiliation":[{"name":"School of Life Sciences, Jilin University, Changchun 130012, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,10,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"E888","DOI":"10.1016\/S2214-109X(17)30293-0","article-title":"Magnitude, emporal trends, and projections of the global prevalence of blindness and distance and near vision impairment: A systematic review and meta-analysis","volume":"5","author":"Bourne","year":"2017","journal-title":"Lancet Glob. Health"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.neuron.2012.06.018","article-title":"Mechanisms of age-related macular degeneration","volume":"75","author":"Ambati","year":"2012","journal-title":"Neuron"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"4714","DOI":"10.1021\/acs.molpharmaceut.7b00859","article-title":"Acid-induced intracellular dissociation of beta-cyclodextrin-threaded polyrotaxanes directed toward attenuating phototoxicity of bisretinoids through promoting excretion","volume":"14","author":"Tamura","year":"2017","journal-title":"Mol. Pharm."},{"key":"ref_4","first-page":"2047","article-title":"Risk factors and clinical significance of prechoroidal cleft in neovascular age-related macular degeneration","volume":"37","author":"Kim","year":"2017","journal-title":"Retin. J. Retin. Vitr. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1001\/archopht.1984.01040031330019","article-title":"Age-related macular degeneration and blindness due to neovascular maculopathy","volume":"102","author":"Ferris","year":"1984","journal-title":"Arch. Ophthalmol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1007\/s00417-008-0889-1","article-title":"Subfoveal choroidal neovascularization complicating 25-gauge trans-retinal choroidal tumor biopsy","volume":"246","author":"Angi","year":"2008","journal-title":"Graef. Arch. Clin. Exp."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1177\/112067210801800616","article-title":"Verteporfin photodynamic therapy for subfoveal choroidal neovascularization in pathologic myopia: A 12-month retrospective review","volume":"18","author":"Costagliola","year":"2008","journal-title":"Eur. J. Ophthalmol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/j.1600-0420.2007.00889.x","article-title":"Central serous chorioretinopathy","volume":"86","author":"Wang","year":"2008","journal-title":"Acta Ophthalmol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"234","DOI":"10.2174\/138945011794182791","article-title":"Perspectives of choroidal neovascularization Therapy","volume":"12","author":"Caputo","year":"2011","journal-title":"Curr. Drug Targets"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"162","DOI":"10.5301\/EJO.2010.3272","article-title":"Regression of peripapillary choroidal neovascularization after oscillatory transpupillary thermotherapy and anti-VEGF pharmacotherapy","volume":"21","author":"Peyman","year":"2011","journal-title":"Eur. J. Ophthalmol."},{"key":"ref_11","first-page":"133","article-title":"Triple therapy for choroidal neovascularization due to agerelated macular degeneration\u2014Verteporfin PDT, bevacimmab, and dexamethasone","volume":"27","author":"Augustin","year":"2007","journal-title":"Retin. J. Retin. Vitr. Dis."},{"key":"ref_12","first-page":"573","article-title":"Same-day triple therapy with photodynamic therapy, intravitreal dexamethasone, and bevacizumab in wet age-related macular degeneration","volume":"29","author":"Bakri","year":"2009","journal-title":"Retin. J. Retin. Vitr. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1159\/000322363","article-title":"A pilot study on the combination treatment of reduced-fluence photodynamic therapy, intravitreal ranibizumab, intravitreal dexamethasone and oral minocycline for neovascular age-related macular degeneration","volume":"225","author":"Sivaprasad","year":"2011","journal-title":"Ophthalmologica"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1021\/acs.molpharmaceut.8b00871","article-title":"In vivo stability profiles of anti-factor D molecules support long-acting delivery approaches","volume":"16","author":"Loyet","year":"2019","journal-title":"Mol. Pharm."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"E305","DOI":"10.1111\/j.1755-3768.2010.02021.x","article-title":"Intravitreal triamcinolone, bevacizumab and pegaptanib for occult choroidal neovascularization","volume":"88","author":"Forte","year":"2010","journal-title":"Acta Ophthalmol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3129\/i09-243","article-title":"Triple therapy for neovascular age-related macular degeneration (verteporfin photodynamic therapy, intravitreal dexamethasone, and intravitreal bevacizumab)","volume":"45","author":"Ehmann","year":"2010","journal-title":"Can. J. Ophthalmol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/aos.12802","article-title":"Anxiety levels and perceived pain intensity during intravitreal injections","volume":"94","author":"Segal","year":"2016","journal-title":"Acta Ophthalmol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"9310","DOI":"10.1167\/iovs.10-7050","article-title":"Endogenous osteopontin involvement in laser-induced choroidal neovascularization in mice","volume":"52","author":"Fujita","year":"2011","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1021\/acs.molpharmaceut.8b00280","article-title":"Theoretical insights into the retinal dynamics of vascular endothelial growth factor in patients treated with ranibizumab, based on an ocular pharmacokinetic\/pharmacodynamic model","volume":"15","author":"Gaffney","year":"2018","journal-title":"Mol. Pharm."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1038\/nm1010-1107","article-title":"Vascular endothelial growth factor and age-related macular degeneration: From basic science to therapy","volume":"16","author":"Ferrara","year":"2010","journal-title":"Nat. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1056\/NEJMra0801537","article-title":"Medical progress: Age-related macular degeneration","volume":"358","author":"Jager","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1097\/ICU.0b013e328329d173","article-title":"Anti-vascular endothelial growth factor therapy for neovascular ocular diseases other than age-related macular degeneration","volume":"20","author":"Ciulla","year":"2009","journal-title":"Curr. Opin. Ophthalmol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.ophtha.2005.02.007","article-title":"Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration\u2014Twelve-week results of an uncontrolled open-label clinical study","volume":"112","author":"Michels","year":"2005","journal-title":"Ophthalmology"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/S0002-9440(10)61231-X","article-title":"Vascular endothelial growth factor expression in the retinal pigment epithelium is essential for choriocapillaris development and visual function","volume":"167","author":"Marneros","year":"2005","journal-title":"Am. J. Pathol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.preteyeres.2008.05.001","article-title":"Vascular endothelial growth factor in eye disease","volume":"27","author":"Penn","year":"2008","journal-title":"Prog. Retin. Eye Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"9764","DOI":"10.1073\/pnas.93.18.9764","article-title":"Involvement of integrins alpha v beta 3 and alpha v beta 5 in ocular neovascular diseases","volume":"93","author":"Friedlander","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S0092-8674(02)00971-6","article-title":"Integrins: Bidirectional, allosteric signaling machines","volume":"110","author":"Hynes","year":"2002","journal-title":"Cell"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1002\/jps.20676","article-title":"Cell adhesion molecules for targeted drug delivery","volume":"95","author":"Dunehoo","year":"2006","journal-title":"J. Pharm. Sci."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1146\/annurev.cellbio.12.1.697","article-title":"RGD and other recognition sequences for integrins","volume":"12","author":"Ruoslahti","year":"1996","journal-title":"Ann. Rev. Cell Dev. Boil."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"154","DOI":"10.7150\/thno\/v01p0154","article-title":"Integrin targeted therapeutics","volume":"1","author":"Millard","year":"2011","journal-title":"Theranostics"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"753","DOI":"10.2174\/187152010794728639","article-title":"Cilengitide: The first anti-angiogenic small molecule drug candidate. Design, synthesis and clinical evaluation","volume":"10","author":"Rechenmacher","year":"2010","journal-title":"AntiCancer Agent Med. Chem."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.ejpb.2014.12.023","article-title":"Current nanotechnology approaches for the treatment and management of diabetic retinopathy","volume":"95","author":"Fangueiro","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000055638","article-title":"Effect of particle size of polymeric nanospheres on intravitreal kinetics","volume":"33","author":"Sakurai","year":"2001","journal-title":"Ophthal. Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"5751","DOI":"10.2147\/IJN.S88109","article-title":"Endothelial cell-targeted pVEGF165 polyplex plays a pivotal role in inhibiting intimal thickening after vascular injury","volume":"10","author":"Tian","year":"2015","journal-title":"Int. J. Nanomed."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"8819","DOI":"10.2147\/IJN.S217038","article-title":"Anti-angiogenic activity of bevacizumab-bearing dexamethasone-loaded PLGA nanoparticles for potential intravitreal applications","volume":"14","author":"Liu","year":"2019","journal-title":"Int. J. Nanomed."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1002\/jcb.22378","article-title":"Bevacizumab and ranibizumab on microvascular endothelial cells: A comparative study","volume":"108","author":"Costa","year":"2009","journal-title":"J. Cell. Biochem."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.biomaterials.2012.10.068","article-title":"Improving antiangiogenesis and anti-tumor activity of curcumin by biodegradable polymeric micelles","volume":"34","author":"Gong","year":"2013","journal-title":"Biomaterials"}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/25\/21\/4897\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:26:34Z","timestamp":1760178394000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/25\/21\/4897"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,23]]},"references-count":38,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2020,11]]}},"alternative-id":["molecules25214897"],"URL":"https:\/\/doi.org\/10.3390\/molecules25214897","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,23]]}}}